Real-world Study of CHina Ozempic cLinicAl pRactice in Patients With Type 2 Diabetes (SCHOLAR) - Trial NCT06351748
Access comprehensive clinical trial information for NCT06351748 through Pure Global AI's free database. This phase not specified trial is sponsored by Novo Nordisk A/S and is currently Enrolling by invitation. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 27000 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Novo Nordisk A/S
Timeline & Enrollment
N/A
Apr 05, 2024
Jun 30, 2024
Primary Outcome
Change in Haemoglobin A1c (HbA1c) level,Change in HbA1c level,Proportion of participants achieving HbA1c less than () 7.0%
Summary
This study is to describe the real-world use and impact of semaglutide once-weekly (OW) among
 participants with type 2 diabetes mellitus (T2DM) in China. Participants diagnosed with T2DM
 who initiated semaglutide OW for the first time between 1 Jan 2022 (the date when semaglutide
 OW was listed in the National Reimbursement Drug List [NRDL] in China] and 28 Feb 2023 (9
 months prior to the data extraction cut-off date of 30 Nov 2023) will be included in this
 study. The study period will be 36 months prior to the first date of participants
 identification period.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06351748
Non-Device Trial